You Z B, Herrera-Marschitz M, Nylander I, Goiny M, Kehr J, Ungerstedt U, Terenius L
Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden.
Brain Res. 1996 Feb 26;710(1-2):241-8. doi: 10.1016/0006-8993(95)01402-0.
In vivo microdialysis was used to study the effects of systemic, as well as intracerebral administration of morphine and naloxone on dynorphin B release in neostriatum and substantia nigra of rats. The release of dopamine (DA), gamma-aminobutyric acid (GABA), glutamate (Glu) and aspartate (Asp) was also investigated. Systemic injection of morphine (1 mg/kg s.c.) induced long-lasting increases in extracellular dynorphin B and GABA levels in the substantia nigra, whereas DA, Glu and Asp levels, measured in the same region, were not significantly affected. No effect on striatal neurotransmitter levels was observed following systemic morphine administration. Local perfusion of the substantia nigra with morphine (100 microM) through the microdialysis probe also increased nigral dynorphin B and GABA levels. Perfusion of the neostriatum with morphine (100 microM) significantly increased GABA and dynorphin B levels in the ipsilateral substantia nigra, but no effect was observed locally. Naloxone blocked the effect of systemic morphine administration on nigral dynorphin B and GABA release, already at a dose of 0.2 mg/kg s.c. Naloxone alone, given either systemically (0.2-4 mg/kg s.c.) or intracerebrally (1-100 microM), did not affect dynorphin B or amino acid levels, either in neostriatum or in substantia nigra. However, naloxone produced a concentration-dependent increase in DA levels. The present results indicate that systemic morphine administration stimulates the release of dynorphin B in the substantia nigra, probably by activating the mu-subtype of opioid receptor, since the effect of morphine on nigral dynorphin B and GABA was antagonized by a low dose of naloxone. The increase in extracellular DA levels produced by high concentrations of naloxone, both in neostriatum and substantia nigra, indicates a disinhibitory effect of this drug on DA release, probably via a non-mu subtype of opioid receptors located on nigro-striatal DA neurones.
采用体内微透析技术研究全身及脑内注射吗啡和纳洛酮对大鼠新纹状体和黑质中强啡肽B释放的影响。同时还研究了多巴胺(DA)、γ-氨基丁酸(GABA)、谷氨酸(Glu)和天冬氨酸(Asp)的释放情况。皮下注射吗啡(1mg/kg)可使黑质细胞外强啡肽B和GABA水平长期升高,而同一区域测得的DA、Glu和Asp水平未受明显影响。全身注射吗啡后,纹状体神经递质水平未观察到变化。通过微透析探针向黑质局部灌注吗啡(100μM)也可使黑质强啡肽B和GABA水平升高。向新纹状体灌注吗啡(100μM)可使同侧黑质GABA和强啡肽B水平显著升高,但局部未观察到影响。纳洛酮皮下注射剂量为0.2mg/kg时即可阻断全身注射吗啡对黑质强啡肽B和GABA释放的作用。单独给予纳洛酮,无论是全身给药(0.2 - 4mg/kg皮下注射)还是脑内给药(1 - 100μM),对新纹状体或黑质中的强啡肽B或氨基酸水平均无影响。然而,纳洛酮可使DA水平呈浓度依赖性升高。目前的结果表明,全身注射吗啡可能通过激活阿片受体的μ亚型刺激黑质中强啡肽B的释放,因为低剂量纳洛酮可拮抗吗啡对黑质强啡肽B和GABA的作用。高浓度纳洛酮在新纹状体和黑质中均可使细胞外DA水平升高,表明该药物可能通过位于黑质 - 纹状体DA神经元上的非μ亚型阿片受体对DA释放产生去抑制作用。